Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Ovarian Epithelial 3Sezary Syndrome 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × Interleukin-12 × Clear all
NCT02960594 2018-11-19

TRT-001

Inovio Pharmaceuticals

Phase 1 Completed
93 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00004070 2017-04-20

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Dana-Farber Cancer Institute

Phase 1/2 Completed
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡